Logo image of AGTC

APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AGTC - US03820J1007 - Common Stock

0.3936 USD
+0 (+1.23%)
Last: 11/30/2022, 8:18:22 PM
0.3936 USD
0 (0%)
After Hours: 11/30/2022, 8:18:22 PM
Fundamental Rating

1

Overall AGTC gets a fundamental rating of 1 out of 10. We evaluated AGTC against 533 industry peers in the Biotechnology industry. AGTC has a bad profitability rating. Also its financial health evaluation is rather negative. AGTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGTC had negative earnings in the past year.
In the past year AGTC has reported a negative cash flow from operations.
AGTC had negative earnings in each of the past 5 years.
In the past 5 years AGTC always reported negative operating cash flow.
AGTC Yearly Net Income VS EBIT VS OCF VS FCFAGTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

With a Return On Assets value of -122.50%, AGTC is not doing good in the industry: 85.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGTC Yearly ROA, ROE, ROICAGTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AGTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGTC Yearly Profit, Operating, Gross MarginsAGTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

AGTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGTC has more shares outstanding
Compared to 1 year ago, AGTC has a worse debt to assets ratio.
AGTC Yearly Shares OutstandingAGTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
AGTC Yearly Total Debt VS Total AssetsAGTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -11.20, we must say that AGTC is in the distress zone and has some risk of bankruptcy.
AGTC has a Altman-Z score of -11.20. This is amonst the worse of the industry: AGTC underperforms 82.71% of its industry peers.
A Debt/Equity ratio of 0.39 indicates that AGTC is not too dependend on debt financing.
AGTC has a worse Debt to Equity ratio (0.39) than 85.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z -11.2
ROIC/WACCN/A
WACC11.71%
AGTC Yearly LT Debt VS Equity VS FCFAGTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

AGTC has a Current Ratio of 1.40. This is a normal value and indicates that AGTC is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.40, AGTC is not doing good in the industry: 88.94% of the companies in the same industry are doing better.
AGTC has a Quick Ratio of 1.40. This is a normal value and indicates that AGTC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AGTC (1.40) is worse than 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
AGTC Yearly Current Assets VS Current LiabilitesAGTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.48% over the past year.
Looking at the last year, AGTC shows a very negative growth in Revenue. The Revenue has decreased by -35.00% in the last year.
The Revenue for AGTC have been decreasing by -61.71% on average. This is quite bad
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A

3.2 Future

AGTC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGTC Yearly Revenue VS EstimatesAGTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B
AGTC Yearly EPS VS EstimatesAGTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGTC. In the last year negative earnings were reported.
Also next year AGTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGTC Price Earnings VS Forward Price EarningsAGTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGTC Per share dataAGTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.55%
EPS Next 3Y9.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED GENETIC TECHNOLOGIES

NASDAQ:AGTC (11/30/2022, 8:18:22 PM)

After market: 0.3936 0 (0%)

0.3936

+0 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2022-11-21/amc
Earnings (Next)02-13 2023-02-13
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.33%
Ins Owner ChangeN/A
Market Cap26.62M
Revenue(TTM)325.00K
Net Income(TTM)-70.23M
Analysts50
Price Target0.37 (-6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.02%
Min EPS beat(2)-37.25%
Max EPS beat(2)-14.78%
EPS beat(4)0
Avg EPS beat(4)-24.61%
Min EPS beat(4)-37.25%
Max EPS beat(4)-14.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.41%
PT rev (3m)N/A
EPS NQ rev (1m)-8.82%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 81.91
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -11.2
F-Score3
WACC11.71%
ROIC/WACCN/A
Cap/Depr(3y)93.46%
Cap/Depr(5y)69.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.96%
EBIT Next 3Y-3.21%
EBIT Next 5Y-0.71%
FCF growth 1Y-48.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.27%
OCF growth 3YN/A
OCF growth 5YN/A

APPLIED GENETIC TECHNOLOGIES / AGTC FAQ

What is the fundamental rating for AGTC stock?

ChartMill assigns a fundamental rating of 1 / 10 to AGTC.


What is the valuation status of APPLIED GENETIC TECHNOLOGIES (AGTC) stock?

ChartMill assigns a valuation rating of 1 / 10 to APPLIED GENETIC TECHNOLOGIES (AGTC). This can be considered as Overvalued.


Can you provide the profitability details for APPLIED GENETIC TECHNOLOGIES?

APPLIED GENETIC TECHNOLOGIES (AGTC) has a profitability rating of 1 / 10.


What is the expected EPS growth for APPLIED GENETIC TECHNOLOGIES (AGTC) stock?

The Earnings per Share (EPS) of APPLIED GENETIC TECHNOLOGIES (AGTC) is expected to grow by 38.73% in the next year.